RT Journal Article
SR Electronic
T1 Access to healthcare as an important moderating variable for understanding geography of immunity levels for COVID-19 - preliminary insights from Poland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267167
DO 10.1101/2021.12.08.21267167
A1 Jarynowski, Andrzej
A1 Belik, Vitaly
YR 2022
UL http://medrxiv.org/content/early/2022/02/21/2021.12.08.21267167.abstract
AB Background Biases in COVID-19 burden and uncertainty in estimation of the corresponding epidemiologic indexes is a known and common phenomenon in infectious diseases. We investigated to what extent healthcare access (HCA) related supply/demand interfered with registered data on COVID-19 in Poland.Material and methods We run a multiple linear regression model with interactions to explain geographic variation in seroprevalence, hospitalizations (on voivodeship – NUTS-2 level) and current (beginning of the 4th wave – 15.09-21.11.2021) case notifications/crude mortality (on poviat – old NUTS-4 level). We took vaccination coverage and cumulative case notifications up to the so called 3rd wave as predictor variables and supply/demand (HCA) as moderating variables.Results HCA with interacting terms (mainly demand) explained to the great extent the variance of current incidence and most variance of current mortality. HCA (mainly supply) is significantly moderating cumulative case notifications till the 3rd wave explaining the variance in seroprevalence and hospitalization.Conclusions Seeking causal relations between vaccination-or infection-gained immunity level and current infection dynamics could be misleading without understanding socio-epidemiologic context such as the moderating role of HCA (sensu lato). After quantification, HCA could be incorporated into epidemiologic models for improved prediction of real disease burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by DFG (German Research Foundation, project number 458528774).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data:seroprevalence, hospitalization, case notifications, crude mortality, vaccination coverage, supply/demand healthcare access indexes. Sources: Statistics Poland, Ministry of Health Poland, Crisis Management PolandI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced and processing scripts are available online at Github https://github.com/ajarynowski/Healtcare_Access_COVID/